Kamada (NASDAQ:KMDA) Rating Lowered to Buy at StockNews.com

StockNews.com lowered shares of Kamada (NASDAQ:KMDA) from a strong-buy rating to a buy rating in a research report report published on Tuesday.

Other analysts have also issued reports about the company. Benchmark initiated coverage on Kamada in a research note on Friday, March 21st. They issued a “buy” rating and a $15.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of Kamada in a research report on Thursday, March 6th.

Kamada Stock Down 1.0 %

Shares of Kamada stock opened at $6.83 on Tuesday. The firm has a market cap of $392.59 million, a PE ratio of 24.39, a P/E/G ratio of 0.97 and a beta of 0.97. Kamada has a fifty-two week low of $4.74 and a fifty-two week high of $9.16. The business’s fifty day moving average is $7.18 and its two-hundred day moving average is $6.29.

Kamada Announces Dividend

The company also recently disclosed a — dividend, which will be paid on Monday, April 7th. Stockholders of record on Monday, March 17th will be paid a $0.20 dividend. The ex-dividend date is Monday, March 17th.

Institutional Trading of Kamada

A number of institutional investors and hedge funds have recently bought and sold shares of KMDA. NewEdge Advisors LLC lifted its position in Kamada by 54.2% during the fourth quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock valued at $143,000 after buying an additional 8,260 shares in the last quarter. Aristides Capital LLC lifted its holdings in shares of Kamada by 12.1% during the 4th quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock valued at $387,000 after acquiring an additional 6,850 shares in the last quarter. Geode Capital Management LLC boosted its position in Kamada by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock worth $178,000 after purchasing an additional 1,549 shares during the period. JPMorgan Chase & Co. acquired a new stake in Kamada in the 4th quarter valued at $67,000. Finally, Public Employees Retirement System of Ohio acquired a new stake in Kamada in the 3rd quarter valued at $77,000. Institutional investors and hedge funds own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.